Cargando…

Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol

INTRODUCTION: Regorafenib was recently approved for patients with pretreated advanced colorectal cancer (aCRC), despite a moderate improvement of the patients’ outcome, and significant toxicities. Based on previous studies showing that early fluorodeoxyglucose-positron emission tomography (FDG-PET)-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hendlisz, Alain, Deleporte, Amélie, Vandeputte, Caroline, Charette, Nicolas, Paesmans, Marianne, Guiot, Thomas, Garcia, Camilo, Flamen, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360786/ https://www.ncbi.nlm.nih.gov/pubmed/25753361 http://dx.doi.org/10.1136/bmjopen-2014-007189

Ejemplares similares

Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient’s outcome in advanced colorectal cancer: the CORIOLAN study
por: Deleporte, Amelie, et al.
Publicado: (2014)

Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials
por: Charette, Nicolas, et al.
Publicado: (2019)

Prognostic Value of the Pace of Tumor Progression as Assessed by Serial (18)F-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The CORIOLAN Trial
por: Camera, Silvia, et al.
Publicado: (2020)

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study
por: Hendlisz, Alain, et al.
Publicado: (2013)

Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer
por: Woff, Erwin, et al.
Publicado: (2016)

The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer
por: Hendlisz, Alain, et al.
Publicado: (2015)

Erratum: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study
por: Hendlisz, Alain, et al.
Publicado: (2015)

Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor
por: Vandeputte, Caroline, et al.
Publicado: (2018)

Regorafenib: Adding to the Armamentarium for Refractory Colorectal Cancer and GIST
por: Roman, Danielle, et al.
Publicado: (2013)

(90)Y-PET/CT-based dosimetry after selective internal radiation therapy predicts outcome in patients with liver metastases from colorectal cancer
por: Levillain, Hugo, et al.
Publicado: (2018)

Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer
por: Buvat, Irène, et al.
Publicado: (2012)

Comparison of PET metabolic indices for the early assessment of tumour response in metastatic colorectal cancer patients treated by polychemotherapy
por: Maisonobe, Jacques-Antoine, et al.
Publicado: (2012)

Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance
por: Kehagias, Pashalina, et al.
Publicado: (2022)

Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
por: Yoon, Sang Eun, et al.
Publicado: (2018)

Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study
por: Dane, Faysal, et al.
Publicado: (2020)

Infiltrative tumour growth pattern correlates with poor outcome in oesophageal cancer
por: Anciaux, Maelle, et al.
Publicado: (2020)

Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer
por: Prager, Gerald, et al.
Publicado: (2017)

A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer
por: Xue, Wu-Song, et al.
Publicado: (2018)

The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer
por: Yoon, Sang Eun, et al.
Publicado: (2019)

Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study
por: Xu, Donghao, et al.
Publicado: (2022)

CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial
por: Rothé, Françoise, et al.
Publicado: (2019)

Postoperative C-reactive protein kinetics predict postoperative complications in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis
por: Asmar, Antoine El, et al.
Publicado: (2020)

Optimizing Mechanical Ventilation in Refractory ARDS
por: Terzi, Nicolas, et al.
Publicado: (2022)

Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib
por: Wong, Andrea Li Ann, et al.
Publicado: (2015)

A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer
por: Su, Guan-Li, et al.
Publicado: (2020)

Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer
por: Wang, Chongkai, et al.
Publicado: (2020)

A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer
por: Miyamoto, Yuji, et al.
Publicado: (2020)

Case report: Efficacy and safety of regorafenib plus fluorouracil combination therapy in the treatment of refractory metastatic colorectal cancer
por: Haque, Emaan, et al.
Publicado: (2022)

Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer
por: Wong, Selina K., et al.
Publicado: (2019)

Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer
por: Fogelman, David, et al.
Publicado: (2018)

Critical appraisal of the use of regorafenib in the management of colorectal cancer
por: Festino, Lucia, et al.
Publicado: (2013)

SHP-1 is a target of regorafenib in colorectal cancer
por: Fan, Li-Ching, et al.
Publicado: (2014)

Molecular profiling in the treatment of colorectal cancer: focus on regorafenib
por: Yan, Yiyi, et al.
Publicado: (2015)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
por: Melosky, Barbara
Publicado: (2016)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2020)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2019)

Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer
por: Yuan, Tao, et al.
Publicado: (2023)

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
por: Ramaswamy, Anant, et al.
Publicado: (2019)

Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third-line or later chemotherapy regimen for refractory metastatic colorectal cancer
por: Tanaka, Akira, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4je416vvec93lr3idp64525fep